Oscillatory Underpinnings of Mismatch Negativity and Their Relationship with Cognitive Function in Patients with Schizophrenia
Open Access
- 17 December 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (12) , e83255
Abstract
Impairments in mismatch negativity (MMN) generation have been consistently reported in patients with schizophrenia. However, underlying oscillatory activity of MMN deficits in schizophrenia and the relationship with cognitive impairments have not been investigated in detail. Time-frequency power and phase analyses can provide more detailed measures of brain dynamics of MMN deficits in schizophrenia. 21 patients with schizophrenia and 21 healthy controls were tested with a roving frequency paradigm to generate MMN. Time-frequency domain power and phase-locking (PL) analysis was performed on all trials using short-time Fourier transforms with Hanning window tapering. A comprehensive battery (CANTAB) was used to assess neurocognitive functioning. Mean MMN amplitude was significantly lower in patients with schizophrenia (95% CI 0.18 - 0.77). Patients showed significantly lower EEG power (95% CI -1.02 - -0.014) in the ~4-7 Hz frequency range (theta band) between 170 and 210 ms. Patients with schizophrenia showed cognitive impairment in multiple domains of CANTAB. However, MMN impairments in amplitude and power were not correlated with clinical measures, medication dose, social functioning or neurocognitive performance. The findings from this study suggested that while MMN may be a useful marker to probe NMDA receptor mediated mechanisms and associated impairments in gain control and perceptual changes, it may not be a useful marker in association with clinical or cognitive changes. Trial-by-trial EEG power analysis can be used as a measure of brain dynamics underlying MMN deficits which also can have implications for the use of MMN as a biomarker for drug discovery.Keywords
This publication has 65 references indexed in Scilit:
- Characterization of Neurophysiologic and Neurocognitive Biomarkers for Use in Genomic and Clinical Outcome Studies of SchizophreniaPLOS ONE, 2012
- Mismatch Negativity Encoding of Prediction Errors Predicts S-ketamine-Induced Cognitive ImpairmentsNeuropsychopharmacology, 2011
- Memory-Based Mismatch Response to Frequency Changes in RatsPLOS ONE, 2011
- Perceptual Measurement in Schizophrenia: Promising Electrophysiology and Neuroimaging Paradigms From CNTRICSSchizophrenia Bulletin, 2011
- Automatic sensory information processing abnormalities across the illness course of schizophreniaPsychological Medicine, 2011
- Neurocognition, insight into illness and subjective quality-of-life in schizophrenia: What is their relationship?Schizophrenia Research, 2011
- Mismatch Negativity, Social Cognition, and Functioning in Schizophrenia PatientsBiological Psychiatry, 2010
- Measurement of mismatch negativity in individuals: A study using single-trial analysisPsychophysiology, 2010
- Gray Matter Deficits, Mismatch Negativity, and Outcomes in SchizophreniaSchizophrenia Bulletin, 2009
- Recent Advances in the Development of Novel Pharmacological Agents for the Treatment of Cognitive Impairments in SchizophreniaSchizophrenia Bulletin, 2007